Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IWM, ARDX, INSM, XBI, MIST, and represent 64.76% of Lion Point Capital's stock portfolio.
- Added to shares of these 8 stocks: KNSA, BBIO, AVDL, MLYS, GERN, NBIX, MIST, RGNX.
- Started 3 new stock positions in BBIO, KNSA, AVDL.
- Reduced shares in these 10 stocks: SMTC (-$69M), IWM (-$34M), Kiniksa Pharmaceuticals, ARDX, Flamel Technologies Sa, HUMA, Travere Therapeutics, TVTX, REPL, BLUE.
- Sold out of its positions in Flamel Technologies Sa, HUMA, REPL, SMTC, TVTX, Travere Therapeutics, Kiniksa Pharmaceuticals.
- Lion Point Capital was a net seller of stock by $-105M.
- Lion Point Capital has $55M in assets under management (AUM), dropping by -69.35%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lion Point Capital
Lion Point Capital holds 27 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 30.5 | $17M | -66% | 83k | 202.89 |
|
| Ardelyx (ARDX) | 11.6 | $6.3M | -18% | 857k | 7.41 |
|
| Insmed Com Par $.01 (INSM) | 8.6 | $4.7M | 70k | 67.00 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 8.5 | $4.6M | 50k | 92.71 |
|
|
| Milestone Pharmaceuticals (MIST) | 5.6 | $3.1M | 2.3M | 1.32 |
|
|
| Geron Corporation (GERN) | 4.9 | $2.7M | +5% | 630k | 4.24 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 4.5 | $2.5M | 2.1M | 1.17 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 3.6 | $2.0M | NEW | 105k | 18.67 |
|
| Mirum Pharmaceuticals Put Option (MIRM) | 2.8 | $1.5M | 45k | 34.19 |
|
|
| Syndax Pharmaceuticals (SNDX) | 2.4 | $1.3M | 65k | 20.53 |
|
|
| Bridgebio Pharma (BBIO) | 2.3 | $1.2M | NEW | 49k | 25.33 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 2.1 | $1.2M | NEW | 83k | 14.06 |
|
| Neurocrine Biosciences (NBIX) | 2.1 | $1.1M | +11% | 8.4k | 137.67 |
|
| Fennec Pharmaceuticals (FENC) | 1.9 | $1.0M | 170k | 6.11 |
|
|
| Mineralys Therapeutics (MLYS) | 1.7 | $924k | +31% | 79k | 11.70 |
|
| Enphys Acquisition Corp Cl A Ord Shs (NFSCF) | 1.6 | $858k | 78k | 10.98 |
|
|
| Jasper Therapeutics Com New (JSPR) | 1.3 | $726k | 32k | 22.70 |
|
|
| Bluebird Bio (BLUE) | 1.2 | $668k | -20% | 678k | 0.98 |
|
| Burgerfi International | 1.0 | $557k | 2.7M | 0.20 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.8 | $424k | +11% | 36k | 11.70 |
|
| Seres Therapeutics (MCRB) | 0.4 | $247k | 341k | 0.72 |
|
|
| Lumos Pharma (LUMO) | 0.4 | $211k | 91k | 2.32 |
|
|
| Microsoft Corporation (MSFT) | 0.1 | $45k | 100.00 | 446.95 |
|
|
| Spruce Biosciences (SPRB) | 0.1 | $39k | 75k | 0.52 |
|
|
| Burgerfi International *w Exp 12/16/202 | 0.0 | $26k | 2.1M | 0.01 |
|
|
| Battalion Oil Corp (BATL) | 0.0 | $25k | -62% | 7.4k | 3.34 |
|
| Alphabet Cap Stk Cl C (GOOG) | 0.0 | $18k | 100.00 | 183.42 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2024 Q2 filed Aug. 14, 2024
- Lion Point Capital 2024 Q1 filed May 15, 2024
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022
- Lion Point Capital 2022 Q2 filed Aug. 15, 2022
- Lion Point Capital 2022 Q1 filed May 16, 2022
- Lion Point Capital 2021 Q4 filed Feb. 14, 2022
- Lion Point Capital 2021 Q3 filed Nov. 15, 2021
- Lion Point Capital 2021 Q2 filed Aug. 16, 2021
- Lion Point Capital 2021 Q1 restated filed May 19, 2021
- Lion Point Capital 2021 Q1 filed May 17, 2021
- Lion Point Capital 2020 Q4 filed Feb. 16, 2021